Apogenix focuses on the development of immuno-oncology therapeutics for the treatment of cancer and other malignant diseases.
Our pipeline comprises several drug candidates that have the potential for broad application in the treatment of oncological and malignant hematological indications.
Asunercept (APG101), a CD95 ligand inhibitor, is currently in clinical development for the treatment of glioblastoma and myelodysplastic syndromes. Preclinical studies in a variety of tumor indications highlight the potential of asunercept in other solid tumors and malignant hematological diseases.
Apogenix has also developed the proprietary HERA technology platform for the construction of novel hexavalent TNFSF receptor agonists for the treatment of cancer. Preclinical experiments have shown that these agonists effectively stimulate the immune system and display potent anti-tumor efficacy in different model systems, thus making them promising candidates for the treatment of solid tumors.
The excellent antitumor efficacy of Apogenix’ TRAIL receptor agonists has been demonstrated in a large number of preclinical studies. Apogenix has entered into a licensing agreement with AbbVie in 2014. In March 2017, AbbVie initiated a clinical phase I study with ABBV-621 in 92 patients suffering from solid tumors, non-Hodgkins´s lymphoma (NHL) or acute myeloid leukemia (AML).